Randomised, Double-Blind, Multi-Centre, 12 Month Extension Study to Evaluate the Safety And Efficacy of Daily Budesonide MMX 6 mg Versus Placebo in the Maintenance of Remission in Subjects With Ulcerative Colitis.
Phase of Trial: Phase III
Latest Information Update: 06 Sep 2016
At a glance
- Drugs Budesonide (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Sponsors Salix Pharmaceuticals
- 22 May 2012 Tolerability analysis assessing the effects of treatment on bone mineral density presented at Digestive Disease Week 2012.
- 22 May 2012 Results presented at the Digestive Disease Week 2012.
- 18 May 2012 Further analyses will be reported at the 2012 Digestive Disease Week meeting, according to a Santarus media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History